Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

November 9, 2022

https://www.globenewswire.com/news-release/2022/11/09/2552523/0/en/Aquestive-Therapeutics-to-Present-Positive-Data-from-Pharmacokinetic-Studies-for-AQST-109-epinephrine-sublingual-film-at-American-Academy-of-Allergy-Asthma-and-Immunology-ACAAI-Ann.html

WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, will present three abstracts recapping positive data from its completed pharmacokinetic studies of AQST-109 (epinephrine sublingual film) at the American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting, which will be held from November 10-14, in Louisville, Kentucky.

Read more at globenewswire.com

Related news for (AQST)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.